These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 25617950)

  • 1. Value of gadoxetic acid-enhanced and diffusion-weighted MR imaging in evaluation of hepatocellular carcinomas with atypical enhancement pattern on contrast-enhanced multiphasic MDCT in patients with chronic liver disease.
    Kim HS; Kim SH; Kang TW; Song KD; Choi D; Park CK
    Eur J Radiol; 2015 Apr; 84(4):555-62. PubMed ID: 25617950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging.
    Motosugi U; Ichikawa T; Sou H; Sano K; Tominaga L; Muhi A; Araki T
    Radiology; 2010 Jul; 256(1):151-8. PubMed ID: 20574092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
    Lee MH; Kim SH; Park MJ; Park CK; Rhim H
    AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic enhancement pattern of HCC smaller than 3 cm in diameter on gadoxetic acid-enhanced MRI: comparison with multiphasic MDCT.
    Park VY; Choi JY; Chung YE; Kim H; Park MS; Lim JS; Kim KW; Kim MJ
    Liver Int; 2014 Nov; 34(10):1593-602. PubMed ID: 24673802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis.
    Park MJ; Kim YK; Lee MH; Lee JH
    Acta Radiol; 2013 Mar; 54(2):127-36. PubMed ID: 23148300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypervascular hepatocellular carcinoma 1 cm or smaller in patients with chronic liver disease: characterization with gadoxetic acid-enhanced MRI that includes diffusion-weighted imaging.
    Kim JE; Kim SH; Lee SJ; Rhim H
    AJR Am J Roentgenol; 2011 Jun; 196(6):W758-65. PubMed ID: 21606265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small (≤1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging.
    Yu MH; Kim JH; Yoon JH; Kim HC; Chung JW; Han JK; Choi BI
    Radiology; 2014 Jun; 271(3):748-60. PubMed ID: 24588677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPIO-enhanced MRI findings of well-differentiated hepatocellular carcinomas: correlation with MDCT findings.
    Kim SH; Lee WJ; Lim HK; Park CK
    Korean J Radiol; 2009; 10(2):112-20. PubMed ID: 19270856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonhypervascular Hypointense Nodules at Gadoxetic Acid-enhanced MR Imaging in Chronic Liver Disease: Diffusion-weighted Imaging for Characterization.
    Hwang J; Kim YK; Jeong WK; Choi D; Rhim H; Lee WJ
    Radiology; 2015 Jul; 276(1):137-46. PubMed ID: 25734551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarker.
    Choi JW; Lee JM; Kim SJ; Yoon JH; Baek JH; Han JK; Choi BI
    Radiology; 2013 Jun; 267(3):776-86. PubMed ID: 23401584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging features of subcentimeter hypointense nodules on gadoxetic acid-enhanced hepatobiliary phase MR imaging that progress to hypervascular hepatocellular carcinoma in patients with chronic liver disease.
    Jang KM; Kim SH; Kim YK; Choi D
    Acta Radiol; 2015 May; 56(5):526-35. PubMed ID: 24838304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small hepatocellular carcinomas in cirrhosis: differences in contrast enhancement effects between helical CT and MR imaging during multiphasic dynamic imaging.
    Hayashida M; Ito K; Fujita T; Shimizu A; Sasaki K; Tanabe M; Matsunaga N
    Magn Reson Imaging; 2008 Jan; 26(1):65-71. PubMed ID: 17566685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiation of small (≤2 cm) hepatocellular carcinomas from small benign nodules in cirrhotic liver on gadoxetic acid-enhanced and diffusion-weighted magnetic resonance images.
    Kwon HJ; Byun JH; Kim JY; Hong GS; Won HJ; Shin YM; Kim PN
    Abdom Imaging; 2015 Jan; 40(1):64-75. PubMed ID: 24997560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypovascular hypointense nodules on hepatobiliary phase gadoxetic acid-enhanced MR images in patients with cirrhosis: potential of DW imaging in predicting progression to hypervascular HCC.
    Kim YK; Lee WJ; Park MJ; Kim SH; Rhim H; Choi D
    Radiology; 2012 Oct; 265(1):104-14. PubMed ID: 22891358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
    Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
    Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.
    Sun HY; Lee JM; Shin CI; Lee DH; Moon SK; Kim KW; Han JK; Choi BI
    Invest Radiol; 2010 Feb; 45(2):96-103. PubMed ID: 20057319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of gadoxetic acid-enhanced magnetic resonance imaging and contrast-enhanced computed tomography with histopathological examinations for the identification of hepatocellular carcinoma: a multicenter phase III study.
    Tsurusaki M; Sofue K; Isoda H; Okada M; Kitajima K; Murakami T
    J Gastroenterol; 2016 Jan; 51(1):71-9. PubMed ID: 26130441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiating malignant from benign hyperintense nodules on unenhanced T1-weighted images in patients with chronic liver disease: using gadoxetic acid-enhanced and diffusion-weighted MR imaging.
    Moon JY; Kim SH; Choi SY; Hwang JA; Lee JE; Lee J
    Jpn J Radiol; 2018 Aug; 36(8):489-499. PubMed ID: 29876721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients.
    Phongkitkarun S; Limsamutpetch K; Tannaphai P; Jatchavala J
    World J Gastroenterol; 2013 Dec; 19(45):8357-65. PubMed ID: 24363528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging--correlation with molecular transporters and histopathologic features.
    Kitao A; Zen Y; Matsui O; Gabata T; Kobayashi S; Koda W; Kozaka K; Yoneda N; Yamashita T; Kaneko S; Nakanuma Y
    Radiology; 2010 Sep; 256(3):817-26. PubMed ID: 20663969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.